Products - Children and teenagers | Topic

Showing 25 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 August 2026
Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital self-help for eating disorders: early value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Epilepsies in children, young people and adults
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
School-based interventions: physical and mental health and wellbeing promotion
Status:
In development
Expected publication date:
TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC

Children and teenagers Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 25 products

12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510

Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]

Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

Digital self-help for eating disorders: early value assessment

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

Epilepsies in children, young people and adults

Leriglitazone for treating andrenoleukodystrophy [ID3903]

Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]

Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]

Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Omburtamab for treating relapsed neuroblastoma [ID1664]

Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

School-based interventions: physical and mental health and wellbeing promotion

Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091

Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557

Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

VTS-270 for treating Niemann-Pick type C1 [ID1267]

Children and teenagers Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 25 products

Status
1 selected